NA webinar: 3/10 11am EST, speakers: Tom and Carl
EMEA webinar: 3/10 2 pm CET, speakers: Christian and Carl
Hydrophilic polymer matrix systems are widely used in oral controlled drug delivery because of their flexibility to obtain a desirable drug release profile, cost effectiveness, and broad regulatory acceptance. As controlled release formulations continue to evolve, so does the need for more time efficient and flexible manufacturing processes. Continuous manufacturing can help to improve control and understanding of the process, increase development and transfer speed, and reduce costs for development, transfer and operations.
In this presentation the latest advances in commercially available HPMC designed for continuous manufacturing will be discussed. Different case studies will demonstrate the versatility of HPMC for continuous manufacturing. These case studies exemplify the importance of collaboration between the pharmaceutical industry and excipient suppliers.
register for our webinar to:
speakers:
Christian Muehlenfeld
Ashland technical leader - Pharmaceuticals Europe
Christian Mühlenfeld is head of the Life Sciences R&D and Technical Sales Service teams for pharma, nutrition, and agriculture in Europe, Middle East and Africa.
Christian has extensive experience in a wide range of technologies including polymer science, immediate and modified release products, bioavailability enhancement and drug stabilization, as well as 3D printing and continuous manufacturing for solid dosage forms.
He is author and co-author of several scientific publications and book chapters.
Tom Dürig
Senior Director, Life Sciences R&D
Ashland Global Holdings
Tom has global responsibility for the Life Sciences R&D function at Ashland, and has over 20 years’ experience in a variety of settings, including R&D, GMP manufacturing at major multi-national corporations and in academia. Tom is internationally recognized for his sustained professional excellence and contribution to the pharmaceutical and nutraceutical sciences in the fields of solid dosage form and delivery system design, excipient technologies and particle and polymer engineering. He holds several patents pertaining to pharmaceutical and nutritional additives, advanced dosage form design and has co-authored over 130 publications, book chapters and conference presentations on these topics.
Carl Allenspach
Associate Director of Manufacturing Science and Technology
Bristol Myers Squibb
Carl is an Associate Director and Business Operations Manager in the Development to Launch group at Bristol Myers Squib, responsible for transitioning new products into manufacturing. He has spent 22 years in formulation development and manufacturing at Searle/Pharmacia/ Pfizer, Novartis and BMS where he has been responsible for early and late stage development, scale-up and technology transfer as well as commercial support. He has been active in AAPS since 2004 with the Manufacturing Science and Engineering section and the Content Advisory Committee where he has held leadership positions. Carl holds a B.S. in Chemistry from Roosevelt University in Chicago and is currently completing his Ph.D. in Pharmaceutical Science at Rutgers University.
©, Ashland. All rights reserved.
